Find your next paid study

Beijing Pearl Biotechnology Limited Liability CompanyNCT07285148

Advanced Non Small Cell Lung Cancer

Imaging of T-cell Activation With [18F]F-araG in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1 Directed Therapy

This pilot study uses \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC t…

CellSight Technologies, Inc.NCT06107374

A Prospective Observational Study on Genomic and Methylation Signatures in Patients with Extensive-Stage Small Cell Lung Cancer and Metastatic Large Cell Neuroendocrine Carcinoma Undergoing Chemo-Immunotherapy

The goal of this observational study is to understand how genomic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults diagnos…

Small Cell Lung CancerLarge Cell Neuroendocrine (NE) TumorsTreatment Failure+3 more

Oncology Center of Biochemical Education And ResearchNCT06717243

~$10 – $1,125

Non Small Cell Lung Cancer (NSCLC)

A Phase 2, Open-Label, Multicenter Study to Investigate the Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Lung Cancer Resection

The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro T…

Integro TheranosticsNCT07276789

~$10 – $7,500

Renal Cell CarcinomaNon Small Cell Lung CancerMelanoma+9 more

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly …

~$10 – $7,500

Diwakar DavarNCT07223424

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung Cancer+3 more

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

Mersana TherapeuticsNCT05514717

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal Cancer+13 more

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and effica…

Tanabe Pharma America, Inc.

Lung CancerNon Small Cell Lung CancerLung Cancer Recurrent

Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy (PORT) for Minimal Residual Disease (MRD) for Lung Cancer: the MRD-PORT Trial

Primary Objective: Evaluate the role of ctDNA positivity in decision making for postoperative therapy for non-small cell lung cancer. The plan for postoperati…

Rutgers, The State University of New JerseyNCT06979661

~$10 – $6,250

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despit…

Non-small Cell Lung CancerEsophageal CancerGastric Cancer+3 more

University of Missouri-ColumbiaNCT02838836

~$10 – $750

Non-small Cell Lung Cancer

A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)

This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell Lung Cancer (NSCLC) which progr…

~$10 – $7,500

BioNTech SENCT06841055

Solid TumorsER+ Breast CancerTriple Negative Breast Cancer, TNBC+2 more

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Jacobio Pharmaceuticals Co., Ltd.NCT05490472

Metastatic Nonsmall Cell Lung Cancer

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic…